Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Clinical trial NCT05269966 · COMPLETED
Trial details
- NCT number
- NCT05269966
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-09
- Primary completion
- 2023-08-29
- Enrollment
- 105
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.